Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

PROMISE Study Examines Trikafta Use Among CF Patients

In the seven months since Vertex Pharmaceuticals’ triple-combo therapy Trikafta (elexacaftor/tezacaftor/ivacaftor) hit the market, people with cystic fibrosis, their doctors, and the Cystic Fibrosis Foundation (CFF) have all given the drug high marks for effectiveness. Trikafta, a CFTR...